0
0
In a significant move to protect public health and curb antimicrobial resistance (AMR), the Ministry of Health and Family Welfare, Government of India, has banned the import, manufacture, sale, and distribution of 34 critical antimicrobials for use in animals. This ban, officially published in the Gazette of India on September 23, 2025, prohibits 15 antibiotics, 18 antivirals, and one antiprotozoal drug for veterinary use across the country.
Key Details of the Ban
The banned substances include crucial antibiotics such as carbapenems, ceftobiprole, ceftaroline, glycopeptides, and oxazolidinones, as well as antivirals including favipiravir, molnupiravir, oseltamivir, ribavirin, and zanamivir. The antiprotozoal drug nitazoxanide is also included. These antimicrobials are recognized for their importance in treating serious human infections and are reserved exclusively for human medical use.
The move follows a draft notification issued on May 22, 2025, which solicited feedback from stakeholders. With no objections received and in consultation with the Drugs Technical Advisory Board (DTAB), the Ministry finalized the ban in alignment with global best practices, including regulations implemented by the European Union.
Public Health Rationale and Global Context
The ban aims to address the growing threat of AMR, a phenomenon where microbes develop resistance to antimicrobial drugs, rendering treatments ineffective and causing severe health risks. The misuse and overuse of antimicrobials in animals—often for growth promotion or disease prevention—accelerate this process, with resistant bacteria capable of transferring to humans via food consumption, contact, or environmental pathways.
India faces significant challenges from AMR, with estimates linking over 600,000 deaths annually to resistant infections. By restricting these critical antimicrobials in animals, the government seeks to preserve their efficacy for treating severe human infections.
“The use of these antimicrobials in animals poses a direct risk to human health through the potential development and spread of drug-resistant infections,” explained Dr. Sheetal, an infectious disease specialist. “This ban is a proactive step to safeguard essential medicines for humans and mitigate AMR’s public health impact.”
Implications for Veterinary Practice and Animal Health
The notification notes that safer alternatives for veterinary use exist in the market, reducing the need for these critical antimicrobials in animals. The ban applies broadly across various animal categories including livestock, poultry, bees, and milch animals, covering all stages of animal production.
Veterinarians and animal health professionals are encouraged to adopt these alternative therapies to ensure animal welfare without compromising public health. The decision aligns with international standards and trade regulations, particularly those of the European Union, enhancing India’s compliance with global antimicrobial stewardship.
Balanced Perspectives and Limitations
While the ban is widely supported by health authorities and experts, some stakeholders voice concerns about potential challenges in animal disease management and economic impacts on farmers. Experts emphasize the need for continued surveillance, research, and investment in veterinary drug development to provide effective and affordable alternatives.
It is also underscored that this ban is one part of a multifaceted approach to managing AMR, complementing efforts in human healthcare, infection control, and public education.
Conclusion
The Ministry of Health and Family Welfare’s decisive ban on 34 key antimicrobials for animal use marks a pivotal step in India’s fight against antimicrobial resistance. By preserving these vital drugs for human use and promoting safer veterinary alternatives, this policy protects public health while aligning India with global best practices.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
